Jeffrey Sosman

October 29, 2015

Investigators find clues to melanoma treatment resistance

Nearly half of all patients with malignant melanoma, the most deadly form of skin cancer, have a mutation in the BRAF gene found in their tumors. Mutations in the BRAF gene turn on a cancer growth switch known as the MAP kinase pathway.

By VUMC News and Communications
September 25, 2014

Bradfords’ strong support bolsters melanoma research

When something attacks you, you want to attack it back. That’s how Lillian “Tooty” Bradford views her late husband James “Jimmy” Bradford Jr.’s decision to make an initial gift to fund melanoma research at Vanderbilt-Ingram Cancer Center (VICC).

By Christina Echegaray
June 19, 2014

VICC researchers in spotlight at national cancer conference

New Vanderbilt research suggests patients with advanced melanoma — the most deadly form of skin cancer — could safely benefit from a combination of immunotherapy and targeted therapies aimed at specific gene mutations.

By VUMC News and Communications
December 19, 2013

VU study identifies new gene fusions in melanoma

Cancer researchers, led by investigators at Vanderbilt-Ingram Cancer Center, have identified two novel gene fusions in melanoma that may be responsive to existing cancer therapies. Melanoma is the most deadly form of skin cancer.

By VUMC News and Communications
December 12, 2013

Sosman to lead national melanoma research team

Jeffrey Sosman, M.D., professor of Medicine and leader of the Vanderbilt Melanoma Program, will head one of two teams of researchers at prominent national institutions investigating acral melanoma, a skin cancer that typically forms on the hands, soles of the feet or under the fingernails.

By VUMC News and Communications
September 26, 2013

Sosman named one of ‘hottest’ researchers in U.S.

Jeffrey Sosman, M.D., professor of Medicine, Ingram Chair for Cancer Research and director of the Vanderbilt Melanoma Program, was named one of the Hottest Scientific Researchers of the last year by Thomas Reuters Science Watch.

By VUMC News and Communications
May 23, 2013

2013 Academic Enterprise Faculty Awards

The 2013 Vanderbilt University Medical Center Academic Enterprise Faculty Awards, which were presented during Wednesday’s Spring Faculty meeting, included awards for Excellence in Teaching and Outstanding Contributions to Research. Award recipients were nominated by their faculty colleagues and chosen by the Academic Enterprise Faculty Awards Selection Committee.
By Bill Snyder
March 28, 2013

Foundation lauds graduate student’s melanoma research

Katherine Hutchinson, a third-year graduate student in Cancer Biology at Vanderbilt University, has won a $10,000 Research Scholar Award from the Joanna M. Nicolay Melanoma Foundation.
By Bill Snyder
October 25, 2012

Combined drug therapy may delay melanoma progression

Combination therapy with two drugs delayed the development of treatment resistance in patients with metastatic melanoma that expresses a specific mutation in the BRAF gene.
By VUMC News and Communications
August 30, 2012

Stand Up to Cancer TV broadcast airs Sept. 7

By VUMC News and Communications
July 26, 2012

Study finds mutation in melanoma sensitive to drug

An uncommon mutation of the BRAF gene in melanoma patients has been found to respond to a specific drug therapy, providing a rationale for routine screening and therapy in melanoma patients who harbor the BRAF L597 mutation.
By VUMC News and Communications
July 12, 2012

New cancer drug shows promise in early testing

By VUMC News and Communications
January 26, 2012

Investigators seek clues to resistance to melanoma drug

Investigators at Vanderbilt-Ingram Cancer Center and several other centers may be one step closer to finding out why some melanoma patients relapse after treatment with a promising new drug.
By VUMC News and Communications
1 2